Skip to content
Primary Menu
Clinical
Medications for Opioid Use Disorder (MOUD)
Buprenorphine Low-Dose Induction using a Cross-Tapering Strategy
Methadone Resources for Providers
Pain or Opioid Withdrawal in Hospitalized Patients
Xylazine Withdrawal and Overdose
Xylazine Wounds
Perinatal Resources for Opioid Use Disorder (PROUD)
Substance Use Navigator Team
Success Stories
Education
Addiction Medicine Fellowship
Working as a Peer in Recovery
How to Mitigate Stigma
All About the X Waiver
Community Advisory Board (CAB)
Research
Clinical Trials
Research in the News
Publications
Harm Reduction
All About Fentanyl
All About Xylazine
How to Use Narcan
Harm Reduction Interest Group
Police-Assisted Diversion
Trainings & Events
Trainings
Upcoming Events
Events Archive
News & Policy
Policy
About Us
Leadership
CAMP Team
Advisory Board
Team Spotlight
Newsletters
Donate
Get Help
Intranasal Naloxone Administration
Post navigation
Previous:
Is It Time for EDs to Play a Central Role in Opioid Use Disorder Treatment?
Next:
Increasing Short- and Long-Term Buprenorphine Treatment Capacity: Providing Waiver Training for Medical Students
Clinical
Medications for Opioid Use Disorder (MOUD)
Buprenorphine Low-Dose Induction using a Cross-Tapering Strategy
Methadone Resources for Providers
Pain or Opioid Withdrawal in Hospitalized Patients
Xylazine Withdrawal and Overdose
Xylazine Wounds
Perinatal Resources for Opioid Use Disorder (PROUD)
Substance Use Navigator Team
Success Stories
Education
Addiction Medicine Fellowship
Working as a Peer in Recovery
How to Mitigate Stigma
All About the X Waiver
Community Advisory Board (CAB)
Research
Clinical Trials
Research in the News
Publications
Harm Reduction
All About Fentanyl
All About Xylazine
How to Use Narcan
Harm Reduction Interest Group
Police-Assisted Diversion
Trainings & Events
Trainings
Upcoming Events
Events Archive
News & Policy
Policy
About Us
Leadership
CAMP Team
Advisory Board
Team Spotlight
Newsletters
Donate
Get Help
